GLPG - Rasio utang marang kapitalisasi buku Galapagos N.V.

Logo grafis Galapagos N.V. (GLPG)

This daily price chart for Galapagos NV (GLPG) illustrates the price action of an asset whose pricing power in the EU is restricted by government regulators, with the current figure standing at 0.00. The business is exposed to the risk of a shift in development strategy and a potential severance of ties with major partners. However, its status as a reputable European brand in cell therapy and small molecules ensures Galapagos NV (GLPG) maintains steady trust among physicians.

GLPG (Galapagos Corp) riwayat Utang marang nilai buku saka 04.07.2022 nganti 08.05.2026
Barang utama Galapagos Genomics

This ratio compares the company's total liabilities to its equity, determining the degree of financial leverage and the overall stability of the balance sheet structure. By analyzing the debt of Galapagos NV (GLPG) relative to its book capitalization, an investor assesses the margin of safety for the development of the decentralized CAR-T platform under strict operational cost control and royalty dependence.

Pesaing Galapagos NV

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik ANIP (ANI Pharmaceuticals Inc)|MNKD: Rasio utang marang kapitalisasi buku|AMPH - Utang-utang marang nilai buku|Utang marang nilai buku Pacira BioSciences PCRX|SPRY - Utang marang modal buku|Utang-utang marang kapitalisasi buku Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku SCPH (scPharmaceuticals, Inc.)|Utang-utang marang nilai buku TECX|Tonix Pharmaceuticals (TNXP) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik sxtchina.com (SXTC)|EPRX (Eupraxia Pharmaceuticals Inc.) - Utang-utang marang kapitalisasi buku|Utang marang aset resik BioHarvest Sciences, Inc. BHST|Invizyne Technologies, Inc. - Utang-utang marang kapitalisasi buku|ORMP: Utang-utang marang kapitalisasi buku|enterabio.com (ENTX) - Rasio utang marang kapitalisasi buku|ipatherapeutics.com (HYFT) - Rasio utang marang kapitalisasi buku|ABVC (ABVC BioPharma, Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku CPIX|QNTM - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku FibroGen Corporation (FGEN)|Utang-utang marang kapitalisasi buku TELO (Telomir Pharmaceuticals)|Utang-utang marang kapitalisasi buku Rani Therapeutics Holdings RANI|Utang-utang marang kapitalisasi buku SNYR|RLYB: Utang marang aset resik|Rasio utang marang kapitalisasi buku LEXX|PULM (Pulmatrix Corporation) - Utang-utang marang nilai buku|PTHL: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Aptorum (APM)|Lyra Therapeutics (LYRA) - Utang marang nilai buku|Rasio utang marang aset resik IBO (Impact BioMedical, Inc.)|TNFA - Rasio utang marang kapitalisasi buku|YCBD - Rasio utang marang nilai buku|PRFX - Utang marang nilai buku|CYTO - Rasio utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku LIPO (Lipella Pharmaceuticals, Inc.)|OPTN (OptiNose Inc) - Utang marang aset resik|Rasio utang marang kapitalisasi buku Pieris|Rasio utang marang kapitalisasi buku PROC|PTPI - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku qlsyy.net (QLI)|SLRN (ACELYRIN) - Utang-utang marang kapitalisasi buku|TFF Pharmaceuticals Inc. - Utang marang aset resik